# Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma

> **NCT05464329** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 24 (actual)

## Conditions studied

- Large B-cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed B-Cell Lymphoma
- Follicular Lymphoma Grade 3B

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** DHAX
- **DRUG:** ICE

## Key facts

- **NCT ID:** NCT05464329
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-03
- **Primary completion:** 2026-01-02
- **Final completion:** 2029-10-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- Genentech, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464329, "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05464329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*